REG - Oxford Biomedica PLC - Admission of Conditional Placing Shares

Oxford BioMedicaAnnouncement

11/03/2022 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220311:nRSK4986Ea&default-theme=true

RNS Number : 4986E  Oxford Biomedica PLC  11 March 2022

Admission of Conditional Placing Shares

Oxford, UK - 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or the "Company"), a leading gene and cell therapy group, confirms that
5,018,134 new ordinary shares (the "Conditional Placing Shares") have this
morning been admitted to the premium listing segment of the Official List of
the Financial Conduct Authority (the "FCA") and to trading on the main market
for listed securities of London Stock Exchange plc.

The Conditional Placing Shares were subscribed for at an issue price of 810
pence per share and have raised gross proceeds of circa £40.6 million for the
Company and represented approximately 5.5% of the Company's issued share
capital as at the last practicable date prior to the posting of the Circular
on 16 February 2022.

Total Voting Rights

Following Admission of the Conditional Placing Shares in accordance with the
FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company's issued
share capital as at 8:00 am on 11 March 2022 consisted of 96,062,640 ordinary
shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held
in treasury.

 

Accordingly, the total number of voting rights in Oxford Biomedica plc at the
date of this notice is 96,062,640.

 

The above figure 96,062,640 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Oxford Biomedica plc
under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 

Oxford Biomedica plc:
         T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Peel Hunt (Sponsor and Joint Bookrunner):         T: +44 (0)20 7418 8900

 

James Steel

Jock Maxwell Macdonald

Sohail Akbar

 

WG Partners (Joint Bookrunner):
                            T: +44 (0)20 3705 9330

 

David Wilson

Claes Spång

Satheesh Nadarajah

 

Consilium Strategic Communications:

 

Mary-Jane Elliott
                   T: +44 (0)7739 788 014

Matthew Neal
                                                             T:
+44 (0)7720 088 468

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group. In January 2022, Oxford Biomedica announced that it was
broadening its leading viral vector offerings by incorporating Homology
Medicines' established AAV capabilities into a newly formed AAV Manufacturing
and Innovation Business in the US with Homology Medicines as a 20% owner. To
date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector
leading lentiviral vector delivery platform (LentiVector®), which the Group
leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam
Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through
which it has long-term economic interests in other potential gene and cell
therapy products. Additionally, the Group has signed a 3-year master supply
and development agreement with AstraZeneca for large-scale manufacturing of
the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than 740 people.
Further information is available at www.oxb.com (http://www.oxb.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEAPDFFSLAEEA